Menu Search
Equities

Sinovac Biotech Ltd

SNVB:DEU

Sinovac Biotech Ltd

Actions
  • Price (EUR)5.50
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 22 2019.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Sinovac Biotech Ltd's revenues fell -69.97% from 1.49bn to 448.27m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 113.87m to a loss of 99.92m.
Gross margin92.09%
Net profit margin-69.19%
Operating margin-103.87%
Return on assets-2.23%
Return on equity-1.51%
Return on investment-3.30%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Sinovac Biotech Ltd fell by 3.01bn. However, the company earned 104.00m from its operations for a Cash Flow Margin of 23.20%. In addition the company used 2.92bn on investing activities and also paid 76.06m in financing cash flows.
Cash flow per share-1.74
Price/Cash flow per share--
Book value per share86.81
Tangible book value per share86.73
More ▼

Balance sheet in USDView more

Sinovac Biotech Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 2.62%.
Current ratio11.39
Quick ratio11.24
Total debt/total equity0.0358
Total debt/total capital0.0262
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		63.89
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.